Current results suggest that inhibition of WIP1 will be most efficient in cancers with wild-type p53 and amplification or gain-of-function mutations of PPM1D, and thus, determination of the status of TP53 and PPM1D in the tumors will be important for predicting the therapeutical outcome of WIP1 inhibitors. This evidence concerns the gene TP53 and cancer.